Lexaria Bioscience (CSE: LXRP-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with British American Tobacco Limited. That company has products sold in over 11 million locations across more than 180 countries.
Bunka telling Proactive the deal is for research and development that will investigate Lexaria's technology for potential use in nicotine products. All costs of the research will be covered by British American Tobacco.
CSE:LXX
Market: CSE
Market Cap: $37.63 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Lexaria Bioscience seeing increased demand for its DehydraTECH drug...
Most read
Lexaria Bio Science and partner Altria complete Phase One of the development...
Lexaria BioScience (OTCQX: LXRP- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver with news the company has seen their Phase One research and development program of oral forms of nicotine delivery finish with Altria Ventures. Bunka says everything went as planned and...
on 07/16/2020
2 min read
Prev article
3 min read
